RPG Life Sciences Targets 25% CAGR in API Business and Plans New Acquisition

The Quick Take

• RPG Life Sciences MD Ashok Nair outlined a 25% CAGR growth target for the company's active pharmaceutical ingredient business
• The company is evaluating a new acquisition within the next 12 months to accelerate its API portfolio expansion
• RPG Life Sciences is positioning its API segment to serve both Indian domestic demand and export markets

RPG Life Sciences' stated ambition for 25% CAGR growth in its API business signals an aggressive expansion strategy in one of India's most strategically important pharmaceutical sub-sectors. Active Pharmaceutical Ingredients (APIs) are the foundational inputs for finished drug formulations, and India's API industry — historically concentrated in Hyderabad and Gujarat — has been undergoing a capital-intensive reconfiguration since China's COVID-era export restrictions highlighted the risks of overconcentration in Chinese API supply. RPG Life Sciences, a mid-sized pharma player with chemistry expertise in select therapeutic areas, is targeting the intersection of import substitution demand from Indian pharma majors and direct export to regulated markets in the US, Europe, and Japan.

The planned acquisition within 12 months represents RPG's recognition that organic growth at 25% CAGR requires both internal capacity expansion and bolt-on chemistry capabilities. The Indian pharma M&A landscape is active: Strides Pharma, Divi's Laboratories, and Sequent Scientific have all made acquisitions in the API and CDMO (Contract Development and Manufacturing) space over the past 18 months, creating a competitive market for acquisition targets with regulated market approvals. RPG's CNBC TV18 disclosure of acquisition intent within a defined timeframe puts pressure on management to identify and close a deal within the FY28 window or face investor questions about strategic credibility. The most likely acquisition targets are small specialty API companies with USFDA-approved facilities seeking scale.

The forward variable is the specific API therapeutic categories RPG targets for acquisition — oncology APIs, antiviral APIs, and biosimilar starting materials command the highest margins and are most strategically differentiated. The macro variable is the US FDA inspection clearance pace for Indian API facilities: USFDA import alerts on Indian manufacturing sites remain the single largest external risk to Indian API exporters' revenue realization. If RPG's acquisition target carries clean USFDA compliance history, the strategic rationale becomes immediately accretive to export revenue. India's Production Linked Incentive (PLI) scheme for APIs — which provides 10-20% revenue incentives on incremental API sales — will also partially fund the 25% CAGR ambition through government subsidy tailwinds.

Synthesized from 1 source.